Head-to-head comparisons of medication uses, side effects, warnings, and more.
Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved to treat adults with cancers that have a tumor marker protein called HER2. These include breast cancer, non-small cell lung cancer (NSCLC), stomach cancer, esophageal cancer, and other solid tumors. Enhertu is a targeted cancer treatment called an antibody-drug conjugate (ADC). It's usually used when certain past treatments haven't worked well. The dose is given as an infusion through the vein, or IV, every 3 weeks. Common side effects include nausea, tiredness, and hair loss.
Herceptin (trastuzumab) is a targeted anticancer treatment for certain HER2-positive cancers. It treats HER2-positive, early-stage, breast cancer (after breast surgery to remove the tumor) and late-stage, metastatic breast cancer (spread to other parts of the body). It can also treat HER2-positive, metastatic stomach cancer. Herceptin (trastuzumab) is most often used together with other anticancer medications, but can also be used by itself. Depending on the type of cancer, Herceptin (trastuzumab) can be injected into a vein (intravenous, IV) or under the skin (subcutaneous, SQ).
^*Side effect percentages listed for Herceptin (trastuzumab) when used by itself.^
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.